05472985 is referenced by 39 patents and cites 23 patents.

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.

Title
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Application Number
61714
Publication Number
5472985
Application Date
September 2, 1994
Publication Date
December 5, 1995
Inventor
Peter L Weissberg
Cambridge
GB
James C Metcalfe
Cambridge
GB
David J Grainger
Cambridge
GB
Agent
Schwegman Lundberg & Woessner
Assignee
NeoRx Corporation
WA, US
IPC
A61K 31/135
View Original Source